Integras Partners LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Integras Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 31,045 shares of the biopharmaceutical company’s stock, valued at approximately $2,868,000. Gilead Sciences makes up 2.4% of Integras Partners LLC’s holdings, making the stock its 11th largest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Swedbank AB boosted its holdings in shares of Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after buying an additional 189,622 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 60.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 1,493 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 565 shares in the last quarter. Nations Financial Group Inc. IA ADV boosted its holdings in shares of Gilead Sciences by 49.9% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 8,447 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 2,813 shares in the last quarter. Aptus Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 3.9% during the 3rd quarter. Aptus Capital Advisors LLC now owns 8,263 shares of the biopharmaceutical company’s stock worth $693,000 after buying an additional 309 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 0.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 184,172 shares of the biopharmaceutical company’s stock worth $15,441,000 after buying an additional 948 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 311,285 shares of company stock valued at $31,284,910. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GILD shares. Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley increased their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a report on Tuesday. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Trading Down 0.6 %

Shares of Gilead Sciences stock opened at $113.35 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a market cap of $141.16 billion, a PE ratio of 306.35, a P/E/G ratio of 0.71 and a beta of 0.21. The stock has a fifty day moving average price of $101.42 and a 200-day moving average price of $92.47. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.79%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.